Destiny Pharma PLC (AIM:DEST), a clinical stage biotech, has raised total gross proceeds of £6.45mln from a placing, subscription and open offer.
The company, which focuses on the development of medicines to prevent life-threatening infections, has applied for the admission of 12.9mln new shares on London’s AIM, it said on Friday.
The fundraising “will enable Destiny Pharma to accelerate the development of its two, late-stage pipeline assets”, Neil Clark, chief executive officer, said in a statement.